Sun Pharmaceutical Industries is currently trading at Rs. 1298.80, up by 2.40 points or 0.19% from its previous closing of Rs. 1296.40 on the BSE.
The scrip opened at Rs. 1297.85 and has touched a high and low of Rs. 1304.10 and Rs. 1291.20 respectively. So far 30706 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1304.10 on 03-Jan-2024 and a 52 week low of Rs. 922.55 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1304.10 and Rs. 1249.80 respectively. The current market cap of the company is Rs. 310761.87 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.44% and 9.07% respectively.
Sun Pharmaceutical Industries has acquired 100% of shares of Libra Merger, a company incorporated in Israel. The objective of acquisition is to facilitate consolidation of business in Israel. Earlier, the company’s specialty product Ilumetri had been included in category B of China's national reimbursement drug list. Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1837.30 |
Dr. Reddys Lab | 1370.60 |
Cipla | 1495.05 |
Lupin | 2252.40 |
Zydus Lifesciences | 981.55 |
View more.. |